WHAT IS CLAIMED IS:

1. A compound of formula (I)



(I)

or a tautomer thereof, stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein

Ring A is selected from



;

Ring B is selected from C_{3-6}cycloalkyl, C_{6-14}aryl, 3-15 membered heterocyclyl and 5 to 14 membered heteroaryl;

L is absent or is ${}_y*–X–(CR^xR^y)_t–*_z$; X is selected from O, NR^{x1} and  ;

each of x, y and z represents a point of attachment;

R^1 is selected from hydroxyl, C_{1-8}alkyl and C_{1-8}alkoxy;

each occurrence of R^2 is independently selected from cyano, halogen, hydroxyl, C_{1-8}alkyl, C_{1-8}alkoxy, C_{1-8}alkoxyC_{1-8}alkyl, haloC_{1-8}alkyl, haloC_{1-8}alkoxy, hydroxyC_{1-8}alkyl, C(O)C_{1-8}alkyl, C_{3-6}cycloalkyl, C(O)C_{3-6}cycloalkyl and 3 to 15 membered heterocyclic ring;

each occurrence of R^3 is independently selected from halogen, cyano, - C_{1-8}alkyl, haloC_{1-8}alkyl and C_{3-6}cycloalkyl;

each occurrence of R^4 is independently selected from halogen, cyano, - C_{1-8}alkyl, haloC_{1-8}alkyl and C_{3-6}cycloalkyl;

each occurrence of R^5 is independently selected from halogen, cyano, - C_{1-8}alkyl, haloC_{1-8}alkyl and C_{3-6}cycloalkyl;

R^a and R^b, which may be the same or different, are each independently selected from hydrogen and C_{1-8}alkyl;

R^x and R^y which may be the same or different, are each independently selected from hydrogen, C_{1-8}alkyl and hydroxyC_{1-8}alkyl; or R^x and R^y together with the carbon atom to which they are attached, form a 3 to 6 membered cycloalkyl ring;

R^{x1} is selected from hydrogen or C_{1-8}alkyl;

'n' is 0, 1, 2 or 3;

'm' is 0, 1 or 2;

'p' is 0, 1 or 2;

'q' is 0, 1, 2 or 3 and

't' is 0, 1, 2 or 3.

2. The compound according to claim 1, wherein ring B is cyclohexyl, phenyl, 6-oxo-1,6-dihydropyridinyl, piperidinyl, piperazinyl, morpholinyl, isoxazolyl, pyrazolyl, thiazolyl, pyridinyl or pyrimidinyl.

3. The compound according to claim 1, wherein L is absent.

4. The compound according to claim 1, wherein L is  ,  , or .

5. The compound according to claim 1, wherein R^1 is hydroxyl, methyl or methoxy.

6. The compound according to claim 1, wherein 'n' is 0.

7. The compound according to claim 1, wherein each R^2 is independently cyano, F, Cl, methyl, ethyl, methoxy, methoxyethyl, trifluoromethyl, cyclopropyl, C(O)methyl, C(O)cyclopropyl or oxetan-3-yl and 'n' is 1 or 2.

8. The compound according to claim 1, wherein 'm' is 0.

9. The compound according to claim 1, wherein R^3 is methyl, *tert*-butyl or trifluoromethyl and 'm' is 1.

10. The compound according to claim 1, wherein 'p' is 0.

11. The compound according to claim 1, wherein one of R^a and R^b is hydrogen and the other is hydrogen or methyl.

12. The compound according to claim 1, wherein R^1 is methyl; R^a is hydrogen and R^b is hydrogen.

13. The compound according to claim 1, wherein R^1 is hydroxyl; R^a is hydrogen and R^b is methyl.

14. The compound according to claim 1, wherein  is  ,  ,  ,  ,  ,  ,  ,  , or  .

15. The compound according to claim 1, wherein  is cyclohexyl, phenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 4-cyanophenyl, 2-cyclopropylphenyl, 2,4-dichlorophenyl, 2-chloro-4-fluorophenyl, 4-chloro-2-fluorophenyl, 2-chloro-4-methylphenyl, 2,4-difluorophenyl, 3,4-difluorophenyl, 2,4-dimethylphenyl, 2-ethylphenyl, 2-fluorophenyl, 4-fluorophenyl, 2-fluoro-4-methylphenyl, 4-fluoro-2-methylphenyl, 4-methoxyphenyl, 4-(trifluoromethyl)phenyl, o-tolyl , *p*-tolyl, 4-acetylpiperazin-1-yl, 4-acetyl-2-methylpiperazin-1-yl, 4-(cyclopropanecarbonyl)piperazin-1-yl, 4,4-difluoropiperidin-1-yl, 4-ethylpiperazin-1-yl, 4-methylpiperazin-1-yl, 4-(2-methoxyethyl)piperazin-1-yl, 1-methyl-6-oxo-1,6-dihydropyridin-3-yl, 4-(oxetan-3-yl)piperazin-1-yl, morpholin-4-yl, (2*S*,6*R*)-2,6-dimethylmorpholin-4-yl, 3,5-dimethylisoxazol-4-yl, 1-methyl-1*H*-pyrazol-4-yl, 4-methylthiazol-5-yl, pyridin-4-yl or pyrimidin-5-yl.

16. The compound according to claim 1, wherein

Ring A is  ,  ,  or  ;

Ring B is cyclohexyl, phenyl, 6-oxo-1,6-dihydropyridinyl, piperidinyl, piperazinyl, morpholinyl, isoxazolyl, pyrazolyl, thiazolyl, pyridinyl or pyrimidinyl;

L is absent or is  ,  or  ;

R^1 is hydroxyl, methyl or methoxy;

R^2 is cyano, F, Cl, methyl, ethyl, methoxy, methoxyethyl, trifluoromethyl, cyclopropyl, C(O)methyl, C(O)cyclopropyl or oxetan-3-yl;

R^3 is methyl, *tert*-butyl or trifluoromethyl;

R^4 is F;

R^a is hydrogen;

R^b is hydrogen or methyl;

‘n’ is 0, 1 or 2;

‘m’ is 0 or 1;

‘p’ is 0 or 1; and

‘q’ is 0.

17. The compound according to claim 1, wherein



is 

, 

, 

, 

, 

,



, 

, 

or 

;



is cyclohexyl, phenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 4-cyanophenyl, 2-cyclopropylphenyl, 2,4-dichlorophenyl, 2-chloro-4-fluorophenyl, 4-chloro-2-fluorophenyl, 2-chloro-4-methylphenyl, 2,4-difluorophenyl, 3,4-difluorophenyl, 2,4-dimethylphenyl, 2-ethylphenyl, 2-fluorophenyl, 4-fluorophenyl, 2-fluoro-4-methylphenyl, 4-fluoro-2-methylphenyl, 4-methoxyphenyl, 4-(trifluoromethyl)phenyl, o-tolyl , *p*-tolyl, 4-acetylpiperazin-1-yl, 4-acetyl-2-methylpiperazin-1-yl, 4-(cyclopropanecarbonyl)piperazin-1-yl, 4,4-difluoropiperidin-1-yl, 4-ethylpiperazin-1-yl, 4-methylpiperazin-1-yl, 4-(2-methoxyethyl)piperazin-1-yl, 1-methyl-6-oxo-1,6-dihydropyridin-3-yl, 4-(oxetan-3-yl)piperazin-1-yl, morpholin-4-yl, (2*S*,6*R*)-2,6-dimethylmorpholin-4-yl, 3,5-dimethylisoxazol-4-yl, 1-methyl-1*H*-pyrazol-4-yl, 4-methylthiazol-5-yl, pyridin-4-yl or pyrimidin-5-yl;

L is absent or is  ;

R^1 is hydroxyl, methyl or methoxy;

R^4 is F;

R^a is hydrogen;

R^b is hydrogen or methyl;

'p' is 0 or 1; and

'q' is 0.

18. The compound according to claim 1, represented by formula (II)



(II)

or a tautomer thereof, stereoisomer thereof or pharmaceutically acceptable salt thereof,

wherein

Ring A is selected from

 ,  ,  ,  ,  ,  ,  and

 ;

Ring B is selected from C_{3-6}cycloalkyl, C_{6-14}aryl, 3-15 membered heterocyclyl and 5 to 14 membered heteroaryl;

each of x and y represents point of attachment;

R^1 is selected from hydroxyl, C_{1-8}alkyl and C_{1-8}alkoxy;

each occurrence of R^2 is independently selected from cyano, halogen, hydroxyl, C_{1-8}alkyl, C_{1-8}alkoxy, C_{1-8}alkoxyC_{1-8}alkyl, haloC_{1-8}alkyl, haloC_{1-8}alkoxy, hydroxyC_{1-8}alkyl, C(O)C_{1-8}alkyl, C_{3-6}cycloalkyl, C(O)C_{3-6}cycloalkyl and 3 to 15 membered heterocyclic ring;

each occurrence of R^3 is independently selected from halogen, cyano, - C_{1-8}alkyl, haloC_{1-8}alkyl and C_{3-6}cycloalkyl;

each occurrence of R^4 is independently selected from halogen, cyano, - C_{1-8}alkyl, haloC_{1-8}alkyl and C_{3-6}cycloalkyl;

R^a and R^b, which may be same or different, are each independently selected from hydrogen and C_{1-8}alkyl;

‘n’ is 0, 1, 2 or 3;

‘m’ is 0, 1 or 2; and

'p' is 0, 1 or 2.

19. The compound according to claim 18, wherein



is

,

,

,

or

;



is phenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 4-cyanophenyl, 2,4-dichlorophenyl, 2-chloro-4-fluorophenyl, 4-chloro-2-fluorophenyl, 2,4-difluorophenyl, 3,4-difluorophenyl, 2,4-dimethylphenyl, 2-ethylphenyl, 2-fluorophenyl, 4-fluorophenyl, 2-fluoro-4-methylphenyl, 4-fluoro-2-methylphenyl, 4-methoxyphenyl, 4-(trifluoromethyl)phenyl, o-tolyl, *p*-tolyl, 4-acetylpiperazin-1-yl, 4-acetyl-2-methylpiperazin-1-yl, 4-(cyclopropanecarbonyl)piperazin-1-yl, 4,4-difluoropiperidin-1-yl, 4-ethylpiperazin-1-yl, 4-methylpiperazin-1-yl, 4-(2-methoxyethyl)piperazin-1-yl, 1-methyl-6-oxo-1,6-dihydropyridin-3-yl, 4-(oxetan-3-yl)piperazin-1-yl, morpholin-4-yl, (2*S*,6*R*)-2,6-dimethylmorpholin-4-yl, 1-methyl-1*H*-pyrazol-4-yl, pyridin-4-yl or pyrimidin-5-yl;

R^1 is hydroxyl, methyl or methoxy;

R^4 is F;

R^a is hydrogen;

R^b is hydrogen or methyl; and

'p' is 0 or 1.

20. The compound according to claim 1, represented by formula (III)



(III)

or a tautomer thereof, stereoisomer thereof or pharmaceutically acceptable salt thereof,
wherein

Ring B is selected from C_{3-6}cycloalkyl, C_{6-14}aryl, 3-15 membered heterocyclyl and 5 to 14 membered heteroaryl;

X is selected from -O-, -NR^{x1}- and  ;

R^1 is selected from hydroxyl, C_{1-8}alkyl and C_{1-8}alkoxy;

each occurrence of R^2 is independently selected from cyano, halogen, hydroxyl, C_{1-8}alkyl, C_{1-8}alkoxy, C_{1-8}alkoxyC_{1-8}alkyl, haloC_{1-8}alkyl, haloC_{1-8}alkoxy, hydroxyC_{1-8}alkyl, C(O)C_{1-8}alkyl, C_{3-6}cycloalkyl, C(O)C_{3-6}cycloalkyl and 3 to 15 membered heterocyclic ring;

each occurrence of R^4 is independently selected from halogen, cyano, - C_{1-8}alkyl, haloC_{1-8}alkyl and C_{3-6}cycloalkyl;

R^a and R^b, which may be same or different, are each independently selected from hydrogen and C_{1-8}alkyl;

R^x and R^y which may be same or different, are each independently selected from hydrogen, C_{1-8}alkyl and hydroxyC_{1-8}alkyl; or R^x and R^y together with the carbon atom to which they are attached, form a 3 to 6 membered cycloalkyl ring;

R^{x1} is selected from hydrogen or C_{1-8}alkyl;

'n' is 0, 1, 2 or 3;

'p' is 0, 1 or 2; and

't' is 0, 1, 2 or 3.

21. The compound according to claim 20, wherein

 is cyclohexyl, phenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-cyclopropylphenyl, 2-chloro-4-fluorophenyl, 2-chloro-4-methylphenyl, 2,4-dimethylphenyl, 4-fluoro-2-methylphenyl, 3,5-dimethylisoxazol-4-yl or 4-methylthiazol-5-yl;

 is  or  , y and z represents point of attachment;

R^1 is hydroxyl, methyl or methoxy;

R^4 is F;

R^a is hydrogen;

R^b is hydrogen or methyl; and

'p' is 0 or 1.

22. The compound according to claim 1, selected from

N-(4-(3-(4-Chlorophenyl)pyrazin-2-yl)phenyl)-2-(4-(1,1-difluoropropyl)phenyl) acetamide;

N-(4-(3-(4-Chlorophenyl)pyrazin-2-yl)phenyl)-2-(4-(1,1-difluoro-2-hydroxy propyl)phenyl)acetamide;

N-(4-(3-(4-Chlorophenyl)pyrazin-2-yl)phenyl)-2-(4-(1,1-difluoro-2-methoxyethyl)phenyl)acetamide;

N-(4-(3-(3-Chlorophenyl)pyrazin-2-yl)phenyl)-2-(4-(1,1-difluoro-2-hydroxypropyl)phenyl)acetamide;

N-(4-(3-(2-Chlorophenyl)pyrazin-2-yl)phenyl)-2-(4-(1,1-difluoropropyl)phenyl) acetamide;

N-(4-(3-(4-Chloro-2-fluorophenyl)pyrazin-2-yl)phenyl)-2-(4-(1,1-difluoropropyl)phenyl) acetamide;

N-(4-(3-(4-Chlorophenyl)pyridin-2-yl)phenyl)-2-(4-(1,1-difluoropropyl)phenyl) acetamide;

2-(4-(1,1-Difluoro-2-hydroxypropyl)phenyl)-*N*-(4-(3-(4-fluorophenyl)pyrazin-2-yl)phenyl)acetamide;

2-(4-(1,1-Difluoro-2-hydroxypropyl)phenyl)-*N*-(4-(3-(3,4-difluorophenyl)pyrazin-2-yl)phenyl)acetamide;

N-(4-(3-(2,4-Difluorophenyl)pyrazin-2-yl)phenyl)-2-(4-(1,1-difluoropropyl)phenyl) acetamide;

2-(4-(1,1-Difluoropropyl)phenyl)-*N*-(4-(3-(2-fluorophenyl)pyrazin-2-yl)phenyl) acetamide;

2-(4-(1,1-Difluoropropyl)phenyl)-*N*-(4-(3-(4-(trifluoromethyl)phenyl)pyrazin-2-yl)phenyl)acetamide;

2-(4-(1,1-Difluoropropyl)phenyl)-*N*-(4-(3-(*p*-tolyl)pyrazin-2-yl)phenyl)acetamide;

2-(4-(1,1-Difluoropropyl)phenyl)-*N*-(4-(3-(4-fluorophenyl)pyridin-2-yl)phenyl)acetamide;

2-(4-(1,1-Difluoropropyl)phenyl)-*N*-(4-(3-phenylpyrazin-2-yl)phenyl)acetamide;

N-(4-(3-(4-Cyanophenyl)pyrazin-2-yl)phenyl)-2-(4-(1,1-difluoropropyl)phenyl) acetamide;

2-(4-(1,1-Difluoropropyl)phenyl)-*N*-(4-(3-(pyridin-4-yl)pyrazin-2-yl)phenyl)acetamide;

2-(4-(1,1-Difluoro-2-hydroxypropyl)phenyl)-*N*-(4-(3-(4,4-difluoropiperidin-1-yl)pyrazin-2-yl)phenyl)acetamide;

2-(4-(1,1-Difluoro-2-hydroxypropyl)phenyl)-*N*-(4-(3-morpholinopyrazin-2-yl)phenyl) acetamide;

2-(4-(1,1-Difluoropropyl)phenyl)-*N*-(4-(5-(4-fluorophenyl)-3-methyl-1*H*-pyrazol-1-yl)phenyl)acetamide;

N-(4-(1-(*tert*-Butyl)-5-(4-fluorophenyl)-1*H*-pyrazol-4-yl)phenyl)-2-(4-(1,1-difluoropropyl)phenyl)acetamide;

N-(4-(1-(*tert*-Butyl)-5-(4-fluorophenyl)-1*H*-pyrazol-4-yl)phenyl)-2-(4-(1,1-difluoro-2-hydroxypropyl)phenyl)acetamide;

2-(4-(1,1-Difluoropropyl)phenyl)-*N*-(4-(3-(1-methyl-1*H*-pyrazol-4-yl)pyrazin-2-yl)phenyl)acetamide;

N-(4-(3-(4-Acetylpiperazin-1-yl)pyrazin-2-yl)phenyl)-2-(4-(1,1-difluoropropyl)phenyl)acetamide;

2-(4-(1,1-Difluoropropyl)phenyl)-*N*-(4-(3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)pyrazin-2-yl)phenyl)acetamide;

N-(4-(3-(4-Chlorophenyl)pyrazin-2-yl)-2-fluorophenyl)-2-(4-(1,1-difluoropropyl)phenyl)acetamide;

2-(4-(1,1-Difluoropropyl)phenyl)-*N*-(4-(3-(4-methoxyphenyl)pyrazin-2-yl)phenyl)acetamide;

2-(4-(1,1-Difluoropropyl)phenyl)-*N*-(4-(5-(4-fluorophenyl)-3-(trifluoromethyl)-1*H*-pyrazol-1-yl)phenyl)acetamide;

N-(4-(5-(2-Chlorophenyl)-3-(trifluoromethyl)-1*H*-pyrazol-1-yl)phenyl)-2-(4-(1,1-difluoropropyl)phenyl)acetamide;

N-(4-(3-(2-Chlorophenyl)pyridin-2-yl)phenyl)-2-(4-(1,1-difluoropropyl)phenyl) acetamide;

2-(4-(1,1-Difluoropropyl)phenyl)-*N*-(4-(3-(o-tolyl)pyrazin-2-yl)phenyl)acetamide;

2-(4-(1,1-Difluoropropyl)phenyl)-*N*-(4-(3-(4-methylpiperazin-1-yl)pyrazin-2-yl)phenyl)acetamide;

2-(4-(1,1-Difluoropropyl)phenyl)-*N*-(4-(3-(4-ethylpiperazin-1-yl)pyrazin-2-yl)phenyl) acetamide;

N-(4-(2-(4-Chlorophenyl)pyridin-3-yl)phenyl)-2-(4-(1,1-difluoropropyl)phenyl) acetamide;

N-(4-(4-(4-Chlorophenyl)pyridin-3-yl)phenyl)-2-(4-(1,1-difluoropropyl)phenyl) acetamide;

2-(4-(1,1-Difluoropropyl)phenyl)-*N*-(4-(3-((2*S*,6*R*)-2,6-dimethylmorpholino)pyrazin-2-yl)phenyl)acetamide;

N-(4-(3-(2-Chlorophenyl)pyrazin-2-yl)phenyl)-2-(4-(1,1-difluoro-2-hydroxypropyl)phenyl)acetamide;

N-(4-(5-(2,4-Dichlorophenyl)-3-methyl-1*H*-pyrazol-1-yl)phenyl)-2-(4-(1,1-difluoropropyl)phenyl)acetamide;

N-(4-(3-(2-Chloro-4-fluorophenyl)pyrazin-2-yl)phenyl)-2-(4-(1,1-difluoro-2-hydroxypropyl)phenyl)acetamide;

2-(4-(1,1-Difluoro-2-hydroxypropyl)phenyl)-*N*-(4-(3-(2-ethylphenyl)pyrazin-2-yl)phenyl)acetamide;

2-(4-(1,1-Difluoropropyl)phenyl)-*N*-(4-(3-(4-(2-methoxyethyl)piperazin-1-yl)pyrazin-2-yl)phenyl)acetamide;

N-(4-(3-(4-Acetyl-2-methylpiperazin-1-yl)pyrazin-2-yl)phenyl)-2-(4-(1,1-difluoropropyl)phenyl)acetamide;

2-(4-(1,1-Difluoropropyl)phenyl)-*N*-(4-(3-(pyrimidin-5-yl)pyrazin-2-yl)phenyl)acetamide;

2-(4-(1,1-Difluoropropyl)phenyl)-*N*-(4-(3-(4-fluoro-2-methylphenyl)pyrazin-2-yl)phenyl)acetamide;

N-(4-(3-(2-Chloro-4-fluorophenyl)pyrazin-2-yl)phenyl)-2-(4-(1,1-difluoropropyl)phenyl) acetamide;

N-(4-(3-(4-Chlorophenyl)pyridin-4-yl)phenyl)-2-(4-(1,1-difluoropropyl)phenyl) acetamide;

2-(4-(1,1-Difluoropropyl)phenyl)-*N*-(4-(3-(2,4-dimethylphenyl)pyrazin-2-yl)phenyl)acetamide;

2-(4-(1,1-Difluoropropyl)phenyl)-*N*-(4-(3-(2-fluoro-4-methylphenyl)pyrazin-2-yl)phenyl)acetamide;

N-(4-(1-(2-Chloro-4-fluorophenyl)-6-oxo-1,6-dihydropyrimidin-2-yl)phenyl)-2-(4-(1,1-difluoropropyl)phenyl)acetamide;

N-(4-(3-(2,4-Dichlorophenyl)pyrazin-2-yl)phenyl)-2-(4-(1,1-difluoropropyl)phenyl) acetamide;

2-(4-(1,1-Difluoro-2-hydroxypropyl)phenyl)-*N*-(4-(3-(2,4-dimethylphenyl)pyrazin-2-yl)phenyl)acetamide;

(*S*)-2-(4-(1,1-Difluoro-2-hydroxypropyl)phenyl)-*N*-(4-(3-(2-ethylphenyl)pyrazin-2-yl)phenyl)acetamide;

(*R*)-2-(4-(1,1-Difluoro-2-hydroxypropyl)phenyl)-*N*-(4-(3-(2-ethylphenyl)pyrazin-2-yl)phenyl)acetamide;

N-(4-(3-(4-(Cyclopropanecarbonyl)piperazin-1-yl)pyrazin-2-yl)phenyl)-2-(4-(1,1-difluoro-2-hydroxypropyl)phenyl)acetamide;

N-(4-(3-((4-Chlorophenyl)(methyl)amino)pyrazin-2-yl)phenyl)-2-(4-(1,1-difluoropropyl)phenyl)acetamide;

N-(4-(3-(Benzyl(methyl)amino)pyrazin-2-yl)phenyl)-2-(4-(1,1-difluoropropyl)phenyl) acetamide;

N-(4-(3-(Benzylamino)pyrazin-2-yl)phenyl)-2-(4-(1,1-difluoropropyl)phenyl)acetamide;

2-(4-(1,1-Difluoropropyl)phenyl)-*N*-(4-(3-((1-phenylethyl)amino)pyrazin-2-yl)phenyl)acetamide;

(*R*)-2-(4-(1,1-Difluoropropyl)phenyl)-*N*-(4-(3-((1-phenylethyl)amino)pyrazin-2-yl)phenyl)acetamide;

(*R*)-2-(4-(1,1-Difluoropropyl)phenyl)-*N*-(4-(3-(methyl(1-phenylethyl)amino)pyrazin-2-yl)phenyl)acetamide;

(*S*)-2-(4-(1,1-Difluoropropyl)phenyl)-*N*-(4-(3-((1-phenylethyl)amino)pyrazin-2-yl)phenyl)acetamide;

(*S*)-2-(4-(1,1-Difluoropropyl)phenyl)-*N*-(4-(3-(methyl(1-phenylethyl)amino)pyrazin-2-yl)phenyl)acetamide;

(*S*)-*N*-(4-(3-((1-(4-Chlorophenyl)ethyl)amino)pyrazin-2-yl)phenyl)-2-(4-(1,1-difluoropropyl)phenyl)acetamide;

(*S*)-*N*-(4-(3-((1-(3-Chlorophenyl)ethyl)amino)pyrazin-2-yl)phenyl)-2-(4-(1,1-difluoropropyl)phenyl)acetamide;

(*S*)-*N*-(4-(3-((1-(4-Chlorophenyl)ethyl)(methyl)amino)pyrazin-2-yl)phenyl)-2-(4-(1,1-difluoropropyl)phenyl)acetamide;

(*S*)-*N*-(4-(3-((1-(2-Chlorophenyl)ethyl)amino)pyrazin-2-yl)phenyl)-2-(4-(1,1-difluoropropyl)phenyl)acetamide;

(*S*)-2-(4-(1,1-Difluoropropyl)phenyl)-*N*-(4-(3-((1-(4-fluoro-2-methylphenyl)ethyl)amino)pyrazin-2-yl)phenyl)acetamide;

N-(4-(3-(((*S*)-1-(2-Chlorophenyl)ethyl)amino)pyrazin-2-yl)phenyl)-2-(4-(1,1-difluoro-2-hydroxypropyl)phenyl)acetamide;

(*S*)-2-(4-(1,1-Difluoropropyl)phenyl)-*N*-(4-(3-((1-(2,4-dimethylphenyl)ethyl)amino) pyrazin-2-yl)phenyl)acetamide;

(*S*)-*N*-(4-(3-((1-(2-Chloro-4-fluorophenyl)ethyl)amino)pyrazin-2-yl)phenyl)-2-(4-(1,1-difluoropropyl)phenyl)acetamide;

N-(4-(3-((Cyclohexylmethyl)amino)pyrazin-2-yl)phenyl)-2-(4-(1,1-difluoro-2-hydroxypropyl)phenyl)acetamide;

N-(4-(3-(((*S*)-1-(4-Chlorophenyl)ethyl)amino)pyrazin-2-yl)phenyl)-2-(4-(1,1-difluoro-2-hydroxypropyl)phenyl)acetamide;

N-(4-(3-(((*S*)-1-(2-Chlorophenyl)ethyl)amino)pyrazin-2-yl)-2-fluorophenyl)-2-(4-(1,1-difluoro-2-hydroxypropyl)phenyl)acetamide;

N-(4-(3-(((*S*)-1-(2-Chlorophenyl)ethyl)amino)pyrazin-2-yl)-3-fluorophenyl)-2-(4-(1,1-difluoro-2-hydroxypropyl)phenyl)acetamide;

N-(4-(3-(Benzyloxy)pyrazin-2-yl)phenyl)-2-(4-(1,1-difluoropropyl)phenyl)acetamide;

2-(4-(1,1-Difluoropropyl)phenyl)-*N*-(4-(3-(1-phenylethoxy)pyrazin-2-yl)phenyl)acetamide;

N-(4-(3-((2-Chloro-4-fluorobenzyl)oxy)pyrazin-2-yl)phenyl)-2-(4-(1,1-difluoropropyl)phenyl)acetamide;

N-(4-(3-(Benzyloxy)pyrazin-2-yl)phenyl)-2-(4-(1,1-difluoro-2-hydroxypropyl)phenyl)acetamide;

(*R*)-2-(4-(1,1-Difluoropropyl)phenyl)-*N*-(4-(3-(1-phenylethoxy)pyrazin-2-yl)phenyl)acetamide;

(*S*)-2-(4-(1,1-Difluoropropyl)phenyl)-*N*-(4-(3-(1-phenylethoxy)pyrazin-2-yl)phenyl)acetamide;

N-(4-(3-(1-(2-Cyclopropylphenyl)ethoxy)pyrazin-2-yl)phenyl)-2-(4-(1,1-difluoropropyl)phenyl)acetamide;

2-(4-(1,1-Difluoro-2-hydroxypropyl)phenyl)-*N*-(4-(3-(1-phenylcyclopropoxy)pyrazin-2-yl)phenyl)acetamide;

(*R*)-*N*-(4-(3-(1-(2-Chlorophenyl)ethoxy)pyrazin-2-yl)phenyl)-2-(4-(1,1-difluoropropyl)phenyl)acetamide;

N-(4-(3-((*R*)-1-(2-Chlorophenyl)ethoxy)pyrazin-2-yl)phenyl)-2-(4-(1,1-difluoro-2-hydroxypropyl)phenyl)acetamide;

(*S*)-*N*-(4-(3-(1-(2-Chlorophenyl)ethoxy)pyrazin-2-yl)phenyl)-2-(4-(1,1-difluoropropyl)phenyl)acetamide;

N-(4-(3-((*S*)-1-(2-Chlorophenyl)ethoxy)pyrazin-2-yl)phenyl)-2-(4-(1,1-difluoro-2-hydroxypropyl)phenyl)acetamide;

N-(4-(3-(2-Chlorophenoxy)pyrazin-2-yl)phenyl)-2-(4-(1,1-difluoropropyl) phenyl)acetamide;

N-(4-(3-((*R*)-1-(2-Chloro-4-methylphenyl)ethoxy)pyrazin-2-yl)phenyl)-2-(4-(1,1-difluoro-2-hydroxypropyl)phenyl)acetamide;

2-(4-(1,1-Difluoropropyl)phenyl)-*N*-(4-(3-((3,5-dimethylisoxazol-4-yl)methoxy)pyrazin-2-yl)phenyl)acetamide;

2-(4-(1,1-Difluoro-2-hydroxypropyl)phenyl)-*N*-(4-(3-(2-(3,5-dimethylisoxazol-4-yl)ethoxy)pyrazin-2-yl)phenyl)acetamide;

N-(4-(3-((2-Chlorobenzyl)oxy)pyrazin-2-yl)phenyl)-2-(4-(1,1-difluoro-2-hydroxypropyl)phenyl)acetamide;

2-(4-(1,1-Difluoro-2-hydroxypropyl)phenyl)-*N*-(4-(3-(2-(4-methylthiazol-5-yl)ethoxy)pyrazin-2-yl)phenyl)acetamide;

N-(4-(3-(Cyclohexylmethoxy)pyrazin-2-yl)phenyl)-2-(4-(1,1-difluoro-2-hydroxypropyl)phenyl)acetamide;

N-(4-(3-(3-(Benzyloxy)azetidin-1-yl)pyrazin-2-yl)phenyl)-2-(4-(1,1-difluoro-2-hydroxypropyl)phenyl)acetamide;

2-(4-(1,1-Difluoro-2-hydroxypropyl)phenyl)-*N*-(4-(3-(((*S*)-1-(2,4-dimethylphenyl)ethyl)amino)pyrazin-2-yl)phenyl)acetamide;

N-(4-(3-(4-(Cyclopropanecarbonyl)piperazin-1-yl)pyrazin-2-yl)phenyl)-2-(4-(1,1-difluoropropyl)phenyl)acetamide;

2-(4-(1,1-Difluoropropyl)phenyl)-*N*-(4-(3-((2-hydroxy-1-phenylethyl)amino)pyrazin-2-yl)phenyl)acetamide;

2-(4-(1,1-Difluoro-2-hydroxypropyl)phenyl)-*N*-(4-(3-((*R*)-1-(2,4-dimethylphenyl)ethoxy)pyrazin-2-yl)phenyl)acetamide or

2-(4-(1,1-Difluoropropyl)phenyl)-*N*-(4-(3-(4-(oxetan-3-yl)piperazin-1-yl)pyrazin-2-yl)phenyl)acetamide and

pharmaceutically acceptable salts thereof.

23. A compound of formula



or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

24. The compound according to claim 23, having formula



or a pharmaceutically acceptable salt thereof.

25. The compound according to claim 23, having formula



or a pharmaceutically acceptable salt thereof.

26. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable excipient.

27. The pharmaceutical composition according to claim 26, wherein the pharmaceutically acceptable excipient is a carrier or diluent.